The short answer
Elective aesthetic treatments are generally deferred during pregnancy and breastfeeding. Botulinum toxin and dermal fillers have never been studied in pregnancy, so there is no safety data supporting use and manufacturers do not recommend it; most clinics therefore decline injectables, deep peels and elective laser outright. Some superficial services may proceed. The defensible approach is a written policy applied consistently, not an ad hoc decision at the chair.
What does the evidence actually say?
The honest answer is that it says almost nothing, and that absence is the reason for caution. Pregnant and breastfeeding women are excluded from aesthetic clinical trials, so there is no controlled safety data for botulinum toxin, hyaluronic acid fillers, deoxycholic acid or most energy-based devices in pregnancy. FDA labeling for botulinum toxin products reflects the lack of adequate and well-controlled studies in pregnant women. Manufacturers do not recommend use, and professional consensus across dermatology and plastic surgery is to postpone elective injectables.
Breastfeeding is a slightly different analysis. Botulinum toxin is a large protein molecule that acts locally, and lactation resources such as the InfantRisk Center describe systemic transfer into milk as unlikely, but the data remain limited and it is not approved for this population. Hyaluronic acid filler safety in lactation is characterized by the FDA as unknown. Most clinicians still defer both.
Non-systemic services sit differently. Laser and light treatments and superficial facials involve no meaningful systemic absorption, and many practices permit selected superficial services in pregnancy — while noting that pregnancy raises melasma and pigmentation risk, which is a clinical reason to defer resurfacing even where safety is not the concern.
How should a policy be structured?
| Service | Typical pregnancy policy | Typical lactation policy |
|---|---|---|
| Botulinum toxin | Defer | Defer |
| Dermal filler | Defer | Defer |
| Deoxycholic acid, sclerotherapy | Defer | Defer |
| PRP | Defer | Defer |
| Medium and deep chemical peels | Defer | Case by case |
| Superficial peels with agents considered lower risk | Case by case | Often permitted |
| Laser hair removal and resurfacing | Commonly deferred | Often permitted |
| Microneedling | Commonly deferred | Case by case |
| Facials, manual lymphatic drainage, lash extensions | Usually permitted with positioning care | Usually permitted |
| Prescription weight-management programs | Contraindicated | Contraindicated |
Weight-management deserves emphasis. GLP-1 receptor agonist labeling directs discontinuation before a planned pregnancy and advises against use during pregnancy, and these programs require a documented pregnancy screening and contraception discussion rather than a checkbox.
What if the client insists?
Two failure modes exist and both are avoidable. The first is treating a pregnant patient because she asked and signed something. A consent form cannot make an untested intervention appropriate, and a signature does not transfer the clinical decision to the patient — the decision to treat remains the clinician's.
The second is refusing badly. Declining service is legitimate, but base it on the treatment and the evidence, never on assumptions about a person's body or family plans, and apply it identically to everyone. Document the conversation, the reason for deferral, the alternatives offered, and the date the patient may return. Offer skincare or genuinely low-risk alternatives so the interaction ends as a deferral rather than a rejection.
If a patient discloses pregnancy after treatment, document the disclosure, the treatment already given, the date, and the referral to her obstetric provider. Do not speculate in the chart about outcomes.
What this means for your paperwork
Ask pregnancy and breastfeeding status on the initial intake and again on a short health-update attestation at every visit, dated and signed, because status changes between appointments and an eight-month-old answer is worthless. Include a clause stating the patient will inform the clinic if she becomes pregnant during a treatment series.
Write the deferral policy into your policies and procedures manual with the service-by-service position above, have the medical director sign and date it, and train staff to apply it identically at the front desk and in the room. Keep a documented deferral note in the chart for every postponed treatment — it is evidence of a functioning screening process, and it is the record that protects you if the patient later claims she was treated while pregnant.
Related questions
This answer is educational and is not legal or medical advice. Requirements vary by state and change over time — verify with your own legal and clinical advisors before applying anything here in practice.